Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jun 7, 2017
NEWTON, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced dosing of the first patient in its pivotal...
-
May 31, 2017
NEWTON, Mass., May 31, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive...
-
May 18, 2017
NEWTON, Mass., May 18, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that interim clinical data from the ongoing...
-
May 4, 2017− Pivotal Phase 3 BOSTON Study Expected to Commence in May 2017 —
NEWTON, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the first quarter 2017 and...
-
May 3, 2017− Anivive Aims to Develop and Commercialize Verdinexor for the Treatment of Cancer in Companion Animals —
NEWTON, Mass., May 03, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, and Anivive Lifesciences, a privately-held biotech company...
-
Apr 27, 2017
NEWTON, Mass., April 27, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report first quarter 2017...
-
Apr 25, 2017
NEWTON, Mass., April 25, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the pricing of a registered underwritten...
-
Apr 24, 2017
NEWTON, Mass., April 24, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it is commencing a registered...
-
Apr 4, 2017Selinexor Achieves Robust and Prolonged Response Rates in Patients with Relapsed or Refractory DLBCL, Including Against Both GCB and Non-GCB Subtypes
NEWTON, Mass., April 04, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced that updated interim clinical data from its Phase...
-
Apr 3, 2017
NEWTON, Mass., April 03, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Justin Renz, Executive Vice President,...